Otros idiomas Pulmonx Corporation

Acciones

LUNG

US7458481014

Tiempo real estimado Cboe BZX Otros sitios de cotización 16:43:12 01/05/2024			Varia. Cinco días.	Varia. 1 de enero.
7,84 ^USD	+3,02 %		+4,65 %	-38,27 %

26/02	Pulmonx Corporation anuncia el tratamiento del primer paciente con el sistema Aeriseal en el ensayo pivotal Convert II	CI
23/02	Las acciones de Pulmonx caen tras la rebaja de Wells Fargo	MT

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Pulmonx to Report First Quarter 2024 Financial Results on May 1, 2024	10/04
Pulmonx Appoints Mehul Joshi as Chief Financial Officer	02/04
Pulmonx Announces Appointment of Mehul Joshi as Chief Financial Officer	02/04
Pulmonx Corporation Announces Chief Financial Officer Changes, Effective April 3, 2024	02/04
Pulmonx Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	15/03
Pulmonx Announces Treatment of the First Patient with the AeriSeal System in CONVERT II Pivotal Trial	27/02
Pulmonx kondigt behandeling aan van de eerste patiënt met het AeriSeal®-systeem in de CONVERT II-studie	27/02
Pulmonx meldet Behandlung des ersten Patienten mit dem AeriSeal®-System in der CONVERT-II-Zulassungsstudie	27/02
Pulmonx annonce le traitement du premier patient par système AeriSeal® dans l'essai pivot CONVERT II	27/02
Pulmonx annuncia il trattamento del primo paziente con il sistema AeriSeal® nello studio pivotale CONVERT II	27/02
Pulmonx Announces Treatment of the First Patient with the AeriSeal® System in CONVERT II Pivotal Trial	26/02
Pulmonx Corporation Announces Treatment of the First Patient with the Aeriseal System in Convert II Pivotal Trial	26/02
North American Morning Briefing : Traders Await -2-	26/02
Pulmonx Shares Fall After Wells Fargo Downgrade	23/02
Earnings Flash (LUNG) PULMONX CORPORATION Reports Q4 Revenue $19.3M, vs. Street Est of $18.2M	21/02
Pulmonx Corporation Provides Earnings Guidance for the Full Year 2024	21/02
Pulmonx Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	21/02
Pulmonx Announces Retirement of CEO Glen French and Appointment of Industry Veteran Steve Williamson as President and Chief Executive Officer	21/02
Pulmonx Reports Fourth Quarter and Full Year 2023 Financial Results	21/02
Pulmonx Announces Retirement of CEO Glen French and Appointment of Industry Veteran Steve Williamson as President and Chief Executive Officer	21/02

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Pulmonx Corporation

Acciones

LUNG

US7458481014

Otros idiomas

Filtros